Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …

The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years
and the claims of success led to calls for reflection. The main body of text of this Commentary …

Aminoglycosides are natural or semisynthetic antibiotics derived from actinomycetes. They
were among the first antibiotics to be introduced for routine clinical use and several …

Abstract Liposomal amphotericin B (AmBisome®; LAmB) is a unique lipid formulation of
amphotericin B. LAmB is a standard of care for a wide range of medically important …

Visceral Leishmaniasis (VL) is a vector-borne disease caused by an intracellular protozoa of
the genus Leishmania that can be lethal if not treated. VL is caused by Leishmania donovani …

Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

Leishmaniasis is a global term for cutaneous and visceral anthroponotic and zoonotic
diseases caused by the vector-borne parasites of the genus Leishmania. These diseases …

Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by Leishmania
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize …

Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …

Endemic in 149 tropical and subtropical countries, neglected tropical diseases (NTDs) affect
more than 1 billion people annually, including 875 million children in developing …